BiotechTube
Stamford Pharmaceuticals

Stamford Pharmaceuticals

Stamford, United States· Est.
stamfordpharmaceuticals.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Stamford Pharmaceuticals is a private, clinical-stage biotech advancing an oncolytic adenovirus platform, SP-002, primarily for skin cancers like Basal Cell Carcinoma (BCC). The company has reported positive Phase 2 results and is planning a Phase 3 trial for 2025/26, while also exploring its vector-drug conjugate platform for pancreatic and bladder cancers. Led by a small, experienced team with industry and investment backgrounds, Stamford is positioned in the growing cell and gene therapy sector but faces significant development and competitive risks common to early-stage oncology biotechs.

OncologyDermatological Oncology

Technology Platform

Oncolytic adenovirus (Adenovirus-5) platform (SP-002) designed to remodel the tumor microenvironment (TME) and a Vector-Drug Conjugate platform for targeted payload delivery.

Opportunities

The lead program targets advanced Basal Cell Carcinoma, a significant orphan drug opportunity with high unmet need where current therapies have limitations.
The platform's potential to remodel the tumor microenvironment could be applied to larger oncology markets like pancreatic and bladder cancer, representing substantial expansion opportunities.
Positive clinical data could attract partnership deals with larger pharmaceutical companies seeking novel immuno-oncology assets.

Risk Factors

The company faces high clinical development risk, as its lead asset must succeed in ongoing and future late-stage trials in a complex disease setting.
As a pre-revenue private company, it carries significant financial risk and will require substantial dilutive funding to reach commercialization.
It operates in the intensely competitive oncology space, facing potential challenges from established and emerging therapies.

Competitive Landscape

Stamford competes in the oncolytic virus and tumor microenvironment modulation space, which includes companies like Amgen (Imlygic), Replimune, and others. In Basal Cell Carcinoma, it directly competes with and aims to combine with approved Hedgehog inhibitors (vismodegib, sonidegib) from companies like Genentech/Roche and Sun Pharma. The broader skin cancer and visceral oncology markets are crowded with large pharma and biotech players advancing immunotherapies and targeted agents.

More companies in Oncology (General) →More companies in United States →